Voyager Therapeutics to Present Preclinical Data from Vectorized Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR) announced the presentation of preclinical data from its vectorized antibody program at the 26th Annual Society for Neuro-Oncology Meeting on Nov. 19, 2021. The presentation, titled AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis, will be delivered by Dan R. Laks, Ph.D., at 4:15 p.m. ET. This represents a significant advancement in the development of AAV gene therapy technology, aiming to treat severe diseases through innovative approaches.

Positive

• Presentation of preclinical data at a notable industry event highlights ongoing research efforts.
• Focus on HER2+ breast cancer brain metastasis indicates potential market expansion into oncology.

Negative

• None.

CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today announced it will present preclinical data from its vectorized antibody program at the 26^th Society for Neuro-Oncology (SNO) Annual Meeting on Nov. 19, 2021.

SNO Oral Presentation Details:
Title: AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis
Abstract Number: EXTH-02
Abstract Session: CNS Metastases
Presenter: Dan R. Laks, Ph.D., Scientist II, Voyager Therapeutics
Presentation Time: 4:15 p.m. ET

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the technology to treat devastating diseases. Proprietary capsids born from the Company’s TRACER^TM screening platform are powering a rich early-stage pipeline of new and second-generation programs and may elevate the field to overcome the limitations of conventional gene therapy vectors across neurologic disorders and other therapeutic areas. voyagertherapeutics.com        LinkedIn        Twitter

FAQ

What is the significance of the data presented by Voyager Therapeutics on Nov. 19, 2021?

The data focuses on AAV-mediated delivery of an antibody targeting HER2+ breast cancer brain metastasis, showcasing advancements in gene therapy.

Who is presenting the preclinical data for Voyager Therapeutics?

Dan R. Laks, Ph.D., Scientist II at Voyager Therapeutics, is the presenter.

What is the title of the presentation at the SNO Annual Meeting?

The presentation is titled 'AAV mediated brain delivery of an ADCC-enhanced antibody obviates xenograft growth in mouse models of HER2+ breast cancer brain metastasis.'

What time is Voyager Therapeutics' presentation scheduled for?

The presentation is scheduled for 4:15 p.m. ET on Nov. 19, 2021.

How does Voyager Therapeutics' research impact the gene therapy market?

The research may enhance the efficacy of gene therapy in treating severe diseases, particularly in oncology.